PT-141

PT-141 (bremelanotide) is a small cyclic peptide that acts as an agonist at the body's melanocortin receptors. It is derived from the melanocortin peptide Melanotan II and works on the brain rather than on blood vessels. It is supplied here as an analytical-grade reference material for laboratory research use only.

Yes. As bremelanotide, sold under the brand name Vyleesi, it received FDA approval in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval is a matter of public record. The material supplied here, however, is a reference material for laboratory research use only, not a medicine.

The route is different. Erectile-dysfunction drugs such as PDE5 inhibitors act on blood flow in the periphery, whereas PT-141 acts centrally, on melanocortin receptors in the brain that are involved in sexual motivation. That central mechanism is the main reason it is of interest in neuroscience research.

Honestly, modest. Its Phase 3 trials met their formal endpoints, but the actual effect sizes were small, and independent re-analyses and critiques have questioned how meaningful the benefits are in practice. It should not be thought of as a dramatic 'enhancer'; the honest picture is a real but small and debated effect.

Chiefly the melanocortin system and the central control of sexual behavior — how activating MC4R and related receptors in the brain influences motivation and arousal. Because it is an approved drug with published trial data, it is also studied as a case in appraising modest clinical evidence. This remains laboratory research, and nothing here is medical advice.